Liquid biopsy for tumor mutational burden predicts the effectiveness of atezolizumab in non-small cell lung cancer treatment
Lung cancer is the principal cause of cancer-related mortality globally. Although there have been significant advances in the treatment of subsets of patients with molecularly defined non-small cell lung cancer (NSCLC), only modest improvements in prognosis have been realized. There is an unfortunate plateau effect associated with traditional chemotherapy. Immunotherapies for advanced NSCLC use immune checkpoint inhibitors (ICIs) to break through this plateau and provide effective treatment. The United States Food and Drug Administration (FDA) approved three ICIs for second-line treatment of NSCLC (nivolumab, pembrolizumab, and atezolizumab), and randomized studies have shown superior overall survival (OS) associated with ICIs, compared to second-line docetaxel (1-4).